Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 1.00 |
| ▸ | XDH | P47989 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563621 | 0.92 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Betuletol SCHEMBL29400938 | 0.92 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| 3,6-Dimethoxy Kaempferol SCHEMBL1156264 | 0.91 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| 3,6-Dimethoxy Kaempferol SCHEMBL30707828 | 0.91 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5073336 | 0.89 | ABCG2 (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27559447 | 0.88 | TUBB4A (0.79) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Axillarin SCHEMBL29929648 | 0.87 | XDH (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Axillarin SCHEMBL1155670 | 0.87 | XDH (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Axillarin SCHEMBL29929599 | 0.87 | XDH (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22855838 | 0.87 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2020136240-A1 | POLYPHENOL-PEPTIDE CONJUGATES FOR NUCLEAR-TARGETED DELIVERY | Universität Wien (AT) | 2020-07-02 | — | — | WO | claimed |
| EP-3673920-A1 | POLYPHENOL-PEPTIDE CONJUGATES FOR NUCLEAR-TARGETED DELIVERY | Universität Wien (AT) | 2020-07-01 | — | — | EP | claimed |
| CN-122029633-A | Based on electron beam pumping-detection resonance spectroscopy | 维也纳工业大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12617913-B2 | Reversible wrinkle patterns and methods of making and using the same | TRUSTEES OF TUFTS COLLEGE (US) | 2026-05-05 | — | — | US | disclosed |
| US-12534538-B2 | Anti-HER2 binding molecules | Certis Therapeutics Pty Ltd (AU) | 2026-01-27 | — | — | US | disclosed |
| US-20260015428-A1 | TARGETING IL17 SIGNALING TO TREAT CANCER AND TO PREVENT AND TREAT ICI INDUCED IMMUNE RELATED ADVERSE EVENTS (IRAES) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2026-01-15 | — | — | US | disclosed |
| US-20260002180-A1 | PLATFORM FOR BIO-BASED PRODUCTION OF HIGH LEVELS OF O-PHOSPHOSERINE, CYSTEATE, OR TAURINE | NATÁUR INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388642-A1 | COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES | CERUS CORPORATION (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382622-A1 | METHODS FOR PREVENTION, DELAY OF PROGRESSION OR TREATMENT OF CHOLESTASIS AND/OR FIBROSIS ASSOCIATED WITH CHOLESTASIS | UNIV BERN (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4200649-B1 | SYSTEMS FOR COINCIDENCE DETECTION IN X-RAY DETECTORS | GE PREC HEALTHCARE LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| CN-1237909-A | Cancer immunotherapy using tumor cells in combination with mixed lymphocytes | UNIV CALIFORNIA (US) | 1999-12-08 | — | — | CN | disclosed |
| EP-0930887-A2 | CANCER IMMUNOTHERAPY USING TUMOR CELLS COMBINED WITH MIXED LYMPHOCYTES | The Regents of the University of California (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0915708-A1 | CANCER IMMUNOTHERAPY USING AUTOLOGOUS TUMOR CELLS COMBINED WITH ALLOGENEIC CYTOKINE-SECRETING CELLS | The Regents of the University of California (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998016238-A2 | CANCER IMMUNOTHERAPY USING TUMOR CELLS COMBINED WITH MIXED LYMPHOCYTES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998004282-A1 | CANCER IMMUNOTHERAPY USING AUTOLOGOUS TUMOR CELLS COMBINED WITH ALLOGENEIC CYTOKINE-SECRETING CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0813209-A2 | Method for erasing non-volatile memory | TEXAS INSTRUMENTS INCORPORATED (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5636162-A | FOR ERASING A NONVOLATILE MEMORY ARRAY | TEXAS INSTRUMENTS INCORPORATED (US) | 1997-06-03 | — | — | US | disclosed |
| US-5357463-A | Method for reverse programming of a flash EEPROM | MICRON SEMICONDUCTOR, INC. (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1989002590-A1 | ENHANCED SYSTEM FOR TRANSMISSION LOSS COMPARISON | CIRCUITS AND SYSTEMS INC. (US) | 1989-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617913-B2 | Reversible wrinkle patterns and methods of making and using the same | CUTA, TTN, MYOF | TUBB4A 1457/4885TUBB 1121/4885TUBA3C 1762/4885 |
| US-20260002180-A1 | PLATFORM FOR BIO-BASED PRODUCTION OF HIGH LEVELS OF O-PHOSPHOSERINE, CYSTEATE, OR TAURINE | UROD, DDC, CBS | TUBB4A 1881/4885TUBB 447/4885TUBA3C 1078/4885 |
| US-20250388642-A1 | COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES | KLRK1, MICA, PBK | TUBB4A 3729/4885TUBB 3599/4885TUBA3C 3182/4885 |
| US-20260015428-A1 | TARGETING IL17 SIGNALING TO TREAT CANCER AND TO PREVENT AND TREAT ICI INDUCED IMMUNE RELATED ADVERSE EVENTS (IRAES) | CD274, PDCD1, PDCD1LG2 | TUBB4A 3372/4885TUBB 3694/4885TUBA3C 4047/4885 |
| US-12534538-B2 | Anti-HER2 binding molecules | IGSF11, ERBB2, IGLV6-57 | TUBB4A 2320/4885TUBB 1590/4885TUBA3C 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.